Table 2 Validation in iDAR in 3 ICU subgroups.
Model validation | AUROC | Sensitivity | Specificity | PPV | NPV | Cutoff |
|---|---|---|---|---|---|---|
iDAR | ||||||
Group 1 vs. 2 + 3 | 0.95 (95% CI 0.89–1) | 97% | 93% | 94% | 96% | > 54.5 |
Group 2 vs. 3 | 0.85 (95% CI 0.71–0.98) | 82% | 81% | 82% | 81% | > 98.4 |
MFI CD64 Neutrophils | ||||||
Group 1 vs. 2 + 3 | 0.84 (95% CI 0.75–0.94) | 70% | 83% | 82% | 71% | > 4.3 |
Group 2 vs. 3 | 0.76 (95% CI 0.59–0.92) | 59% | 81% | 77% | 65% | > 8.5 |
